Ocugen (NASDAQ:OCGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01, Zacks reports. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The firm had revenue of $1.48 million during the quarter.
Ocugen Stock Performance
Shares of OCGN stock opened at $0.67 on Friday. The firm has a market cap of $195.80 million, a price-to-earnings ratio of -3.72 and a beta of 4.21. Ocugen has a 52-week low of $0.52 and a 52-week high of $2.06. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The company's 50 day moving average is $0.66 and its 200 day moving average is $0.76.
Analyst Ratings Changes
Several research analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Ocugen in a research report on Thursday, March 6th. Chardan Capital raised their price target on Ocugen from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th.
Check Out Our Latest Research Report on OCGN
Ocugen Company Profile
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
